Verified reporting on patents, licensing, invention commercialisation, intellectual-property policy and the disputes that shape who can build what comes next. Updated daily.
The government wants the UKIPO to examine suspicious design filings, permit 30-month deferred publication and expressly protect animations and transitions. Most changes are not yet law, and no implementation timetable has been set.
Read story
The appeals court says software disclosed to a reseller can retain trade-secret protection when access is governed by licences and confidentiality duties. SS&C’s case against Arcesium may proceed, but the ruling does not find that misappropriation occurred.
Read story
The CJEU’s first generative-AI case draws a legal line between reporting facts and recognizably reusing journalism. The opinion is not a judgment, but it could shape how grounded chatbots retrieve, summarize and pay for news across the EU.
Read story
The Federal Circuit affirmed that Sonos does not infringe Google’s digital-rights-management patent because grouped speakers do not all directly use the claimed private key. The nonprecedential ruling shows how a few technical words can decide a connected-device patent case before trial.
Read story
The Unified Patent Court has held Enanta’s European coronavirus-protease patent invalid and rejected its infringement case against Pfizer’s Paxlovid across 18 participating states. The cross-border result is clear; the legal and technical reasoning is not, because the judgment has not been made public.
Read story
A US appeals court reversed a $9.15 million attorneys’ fee award against ChromaDex and Dartmouth, finding that their defense of nicotinamide-riboside supplement patents was not exceptionally meritless. The decision does not revive the invalid claims, but it draws a consequential line between losing a natural-product patent case and litigating one unreasonably.
Read story
A WIPO Secretariat report gives patent offices a menu of choices for proving human contribution, handling AI-generated disclosures and deciding when routine access to AI makes an invention obvious. The options now go before member states; they are not new global rules.
Read story
The appeals court reversed an order compelling a patent buyer’s unredacted purchase agreement after Europe’s Unified Patent Court had rejected the same evidence request as premature. The ruling limits, but does not eliminate, U.S. discovery assistance for foreign patent cases.
Read story
The agreement would close a decade-old antitrust fight over insulin-pen patents listed in the FDA’s Orange Book. A court had already called the listings improper and exclusionary, but causation, Sanofi’s defense and damages remained unresolved.
Read story